- Home
- NRXS vs TLPH Comparison
NRXS vs TLPH Comparison
Compare NRXS & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- TLPH
- Stock Information
- Founded
- NRXS 2011
- TLPH 2005
- Country
- NRXS United States
- TLPH United States
- Employees
- NRXS N/A
- TLPH N/A
- Industry
- NRXS
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- TLPH Health Care
- Exchange
- NRXS Nasdaq
- TLPH Nasdaq
- Market Cap
- NRXS 13.0M
- TLPH 10.6M
- IPO Year
- NRXS 2023
- TLPH 2011
- Fundamental
- Price
- NRXS $2.77
- TLPH $0.42
- Analyst Decision
- NRXS Strong Buy
- TLPH Strong Buy
- Analyst Count
- NRXS 1
- TLPH 1
- Target Price
- NRXS $7.00
- TLPH $6.00
- AVG Volume (30 Days)
- NRXS 85.1K
- TLPH 919.4K
- Earning Date
- NRXS 08-08-2025
- TLPH 08-13-2025
- Dividend Yield
- NRXS N/A
- TLPH N/A
- EPS Growth
- NRXS N/A
- TLPH N/A
- EPS
- NRXS N/A
- TLPH N/A
- Revenue
- NRXS $2,934,945.00
- TLPH $27,000.00
- Revenue This Year
- NRXS $138,883.78
- TLPH N/A
- Revenue Next Year
- NRXS $118.59
- TLPH $14,533.26
- P/E Ratio
- NRXS N/A
- TLPH N/A
- Revenue Growth
- NRXS 27.52
- TLPH N/A
- 52 Week Low
- NRXS $1.33
- TLPH $0.38
- 52 Week High
- NRXS $6.20
- TLPH $1.19
- Technical
- Relative Strength Index (RSI)
- NRXS 57.38
- TLPH 42.40
- Support Level
- NRXS $2.55
- TLPH $0.38
- Resistance Level
- NRXS $2.92
- TLPH $0.79
- Average True Range (ATR)
- NRXS 0.17
- TLPH 0.06
- MACD
- NRXS 0.03
- TLPH -0.00
- Stochastic Oscillator
- NRXS 78.26
- TLPH 10.51
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.